Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Choice Particularly Important In Medicare Population – Industry Study

Executive Summary

Drug plans for the elderly should cover a wide range of drugs within each class, a study sponsored by the Pharmaceutical Research & Manufacturers of America concludes

You may also be interested in...

COX-2s, Statins Have No Class In USP Medicare Draft Formulary

U.S. Pharmacopeia has relegated some of the pharmaceutical industry's biggest blockbuster drug "classes" to the status of "recommended subdivisions" in its draft model Medicare formulary

USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

U.S. Pharmacopeia's draft model for Medicare prescription drug formularies establishes 146 unique therapeutic categories and pharmacologic classes, falling in between the numbers of drug groups sought by drug manufacturers and PBMs

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts